WO1994014831A1 - Dihydropyrimidine nucleosides with antiviral properties - Google Patents
Dihydropyrimidine nucleosides with antiviral properties Download PDFInfo
- Publication number
- WO1994014831A1 WO1994014831A1 PCT/CA1993/000553 CA9300553W WO9414831A1 WO 1994014831 A1 WO1994014831 A1 WO 1994014831A1 CA 9300553 W CA9300553 W CA 9300553W WO 9414831 A1 WO9414831 A1 WO 9414831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dihydro
- azido
- deoxythymidine
- bromo
- chloro
- Prior art date
Links
- 0 C*C(CO)OC(*)N(C=C(C)C(N1)=O)C1=O Chemical compound C*C(CO)OC(*)N(C=C(C)C(N1)=O)C1=O 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Definitions
- the present invention relates to pharmaceutical compounds. More particularly, the invention provides new unnatural 5,6-dihydropyrimidine nucleoside derivatives, or non- toxic pharmaceutically acceptable salts thereof, having useful physiological antiviral effects, particularly anti-human immunodeficiency virus (anti-HIV) properties which are useful in the treatment of acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
- anti-HIV anti-human immunodeficiency virus
- the invention relates to such compounds and compositions thereof, and to processes for making and using them.
- HIV-1 RT Human immunodeficiency virus-1 reverse transcriptase plays an important role in the life cycle of the virus and has been a major target for the design of drugs to combat AIDS:
- HIV-1 RT inhibitors are pyrimidine nucleoside analogs such as 3'-azido-3'-deoxythymidine (AZT), 3'-fluoro-3'- deoxythymidine (FT) and 2',3'-didehydro-2' ,3'- dideoxythymidine (d4T). These compounds are converted into their triphosphates by cellular enzymes, the triphosphates are then recognized by HIV-1 RT as substrates.
- AZA 3'-azido-3'-deoxythymidine
- FT 3'-fluoro-3'- deoxythymidine
- d4T 2',3'-didehydro-2' ,3'- dideoxythymidine
- AZT deoxyribonucleic acid
- the lipophilicity of a compound can be described as the partition coefficient (P) of a drug between 1-octanol
- halogen atoms in position 5 in conjunction with an alkoxy, hydroxy or azido substituent in position 6 increase lipophilicity thereby resulting in an increased ability to penetrate into the CNS.
- anti-HIV anti-human immunodeficiency virus
- Such compounds exhibit anti-human immunodeficiency virus (anti-HIV) activity and may also be useful to treat other clinical conditions such as hepatitis B viral infections and other viral infections.
- such compounds have a longer biological half-life allowing for a longer duration of action and they exhibit an increasing drug stability and a decreasing toxicity.
- such compounds may serve as pro-drugs, since a reducing agent (such as glutathione in vivo) would regenerate the 5,6-olefinic bond releasing AZT, FT or d4T.
- the present invention relates to new 5,6-dihydro- pyrimidine derivatives and non-toxic, pharmaceutically acceptable salts thereof (as well as pharmaceutical compositions containing them).
- the new compounds according to the present invention have the general formula:
- R 1 is a halogen
- R 2 is a hydroxy, alkoxy group or azido
- halogen as used herein means fluorine, chlorine, bromine or iodine.
- alkoxy as used herein means substituents of straight and branched chain aliphatic alcohols having from 1 to 16 carbon atoms.
- diastereomer means the (5R,6R), (5S,6S), (5R,6S) or (5S,6R) configuration.
- the 5-halo-6-alkoxy-5,6-dihydrothymidine derivatives are prepared by reacting a thymidine analog of the formula:
- R 1 , R 2 and X-Y are as defined above.
- the reactions are allowed to take place in inert organic solvents such as tetrahydrofuran, dioxane or dimethoxyethane when the alkyl alcohol of formula (IV) is a solid.
- compounds of formula (I) can also be prepared by reacting a thymidine analog of formula (II) wherein X-Y is as defined above, with an electrophilic source of halogen of the formula:
- R 1 is a member selected from the group consisting of iodo, bromo and chloro, in the presence of an alkyl alcohol of formula (IV) wherein R 2 is as defined as above and glacial acetic acid, allowing the reaction to occur at 25°C to convert to 5-halo-6-alkoxy-5,6-dihydrothymidine derivatives of the formula (I) wherein R 1 , R 2 and X-Y are as defined as above.
- inert organic solvents such as dimethoxyethane, dioxane or tetrahydrofuran (preferably dimethoxyethane).
- the 5-halo-6-azido-5,6-dihydro thymidine derivatives are prepared by reacting a thymidine analog of the formula (II) wherein X-Y is as defined as above, with an electrophilic source of halogen of the formula (V) wherein R 1 is as defined above, in an inert organic solvent such as dimethoxyethane, dioxane or tetrahydrofuran, preferably dimethoxyethane, and an alkali metal azide of the formula (VI):
- R 2 -M (VI) wherein R 2 is an azido group and M is selected from a group consisting of sodium, lithium and potassium, prefer ably sodium, in a water solvent, allowing the reaction to occur in the -5°C to 25°C range to convert to 5-halo-6- azido-5,6- dihydrothymidine diastereomers of the formula:
- R 1 is a member selected from the group consisting of iodo, bromo and chloro
- R 2 is an azido substituent
- X-Y is as defined above.
- the 5-halo-6-hydroxy-5,6-dihydrothymidine derivatives are prepared by reacting a thymidine analog of formula (II) wherein X-Y is as defined above, with an electrophilic source of halogen of the formula (V) wherein R 1 is as defined above, in water as a solvent, allowing the reaction to occur at 0°C to convert to 5-halo-6- hydroxy-5,6-dihydrothymidine diastereomers of the formula (I) wherein R 1 is a member selected from the group consisting of iodo, bromo and chloro, R 2 is a hydroxyl substituent and X-Y is as defined above.
- Suitable pharmaceutically acceptable phosphate forms of these compounds include the 5'-O-monophosphate, 5'-O- diphosphate and 5'-O-triphosphate derivatives.
- a liquid carrier a carrier such as water or polyethylene glycol, or other physiologically acceptable solvents or dispersing liquids can be used.
- a carrier such as water or polyethylene glycol, or other physiologically acceptable solvents or dispersing liquids
- solid or liquid carriers may be used.
- One commonly used solid carrier is gum acacia, but others are also suitable.
- An operative dosage range is between about 0.01 and 200 mg/kg, preferably between 0.1 and 20 mg/kg.
- non-limitative examples illustrate some selective methods for producing the compounds according to the present invention, as well as comparative data illustrating the anti-human immunodeficiency virus (anti-HIV) effect of representative compounds according to the present invention.
- anti-HIV anti-human immunodeficiency virus
- the starting materials for the preparation of compounds of formula (I), viz the thymidine analogs of formula (II), the electrophilic forms of halogen of formula (III) and formula (V), the alkyl alcohols of formula (IV), and azides of formula (VI) are either known or are conveniently prepared from known starting materials from methods known per se.
- Chlorine gas (4.7 g) was bubbled slowly into a suspension of 3'-azido-3'-deoxythymidine (10 g, 37.4 mmol) in 98% ethanol (500 mL) at 0°C with stirring until the light yellow-green color of the resulting solution persisted.
- the pH of this solution was adjusted to 6.5 using a solution of sodium hydroxide in ethanol and the mixture was filtered.
- N-Chlorosuccinimide (0.2 g, 1.5 mmol) was added to a solution of 3'-azido-3'-deoxythymidine (0.2 g, 0.75 mmol) in methanol (10 mL) and glacial acetic acid (0.6 mL) with stirring and the reaction was allowed to proceed at 25°C for 15 h. At this time additional N-chlorosuccinimide (0.2 g, 1.5 mmol) and glacial acetic acid (0.6 mL) were added and the reaction was allowed to proceed at 25°C for 24 h with stirring prior to neutralization to pH 6.5 using methanolic sodium hydroxide.
- 1 H NMR (CDCl 3 ) ⁇ 1.80 (s, 3H, C-5 CH 3 ) , 2.30 and 2.63 (two m, 1H each, H-2') , 3.46 (s, 3H, OCH 3 ) , 3.82 (m, 1H, H-5') , 3.96 (m, 2H, H-4', H-5") , 4.32 (m, 1H, H-3') , 4.90 (s, 1H, H-6) , 5.92 (d, J 1 ' , 2' 6.0 Hz, 1H, H-1') , 8.80 (s, 1H, NH, exchanges with deuterium oxide) ; 13 C NMR (CDCI 3 ) ⁇ 21.60 (CH 3 ) , 36.95 (C-2') , 57.36 (OC
- N-Bromosuccinimide 80 mg, 0.44 mmol was added in aliquots to a suspension of 2',3'-didehydro-2',3'- dideoxythymidine (0.1 g, 0.44 mmol) in water (5 mL) at 0°C with stirring. The initial yellow color produced upon addition of each aliquot of N-bromosuccinimide disappeared rapidly. After all the N-bromosuccinimide had been added, the reaction mixture was stirred for 20 min at 0°C.
- N-Bromosuccinimide 36 mg, 2 mmol was added in aliquots to a precooled (-5°C) suspension prepared by mixing a solution of 3'-azido-3'-deoxythymidine (52 mg, 2 mmol) in dimethoxyethane (10 mL) and a solution of sodium azide (52 mg, 8 mmol) in water (0.125 mL) with stirring.
- the initial yellow color produced upon addition of each aliguot of N-bromosuccinimide quickly disappeared.
- the test is designed to measure the efficacy against HIV for drugs acting at any stage of the virus reproductive cycle and involves the killing of T4 lymphocytes by HIV.
- test drug is dissolved in dimethylsulfoxide, then diluted 1:100 in cell culture medium before preparing serial half-logio dilutions.
- T4 lymphocytes CEM cell line
- Uninfected cells with the test drug serve as a toxicity control
- infected and uninfected cells without the test drug serve as basic controls.
- Cultures are incubated at 37°C in a 5% CO 2 atmosphere for 6 days.
- the tetrazolium salt, XTT is added to all wells, and cultures are incubated to allow formazan color development by viable cells.
- Test drug-treated virusinfected cells are compared with test drug-treated non- infected cells and with other appropriate controls (untreated infected and untreated noninfected cells, test drug-containing wells without cells, etc.) on the same plate [see O.W. Weislow, R. Kiser, D. Fine, J. Bader, R.H. Shoemaker, M.R. Boyd, J. Natl. Cancer Inst., 81 , 577 (1989)].
- the test results are shown in the following Table IV, the compounds listed being comparable to 3'-azido-3'-
- IC 50 value is the test drug concentration which results in a 50% survival of uninfected control cells (eg. cytotoxic activity of the test drug)
- the EC 50 value is the test drug concentration which produces a 50% survival of HIV infected cells relative to uninfected controls (eg. in vitro anti-HIV activity)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56910/94A AU5691094A (en) | 1992-12-18 | 1993-12-20 | Dihydropyrimidine nucleosides with antiviral properties |
EP94902577A EP0626970A1 (en) | 1992-12-18 | 1993-12-20 | Dihydropyrimidine nucleosides with antiviral properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99372692A | 1992-12-18 | 1992-12-18 | |
US07/993,726 | 1992-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994014831A1 true WO1994014831A1 (en) | 1994-07-07 |
Family
ID=25539858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1993/000553 WO1994014831A1 (en) | 1992-12-18 | 1993-12-20 | Dihydropyrimidine nucleosides with antiviral properties |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0626970A1 (en) |
AU (1) | AU5691094A (en) |
CA (1) | CA2130265A1 (en) |
WO (1) | WO1994014831A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022778A1 (en) * | 1995-01-27 | 1996-08-01 | Emory University | Derivatives of succinamide and their use as metalloproteinase inhibitor |
US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
WO1999048902A1 (en) * | 1998-03-25 | 1999-09-30 | Parker Hughes Institute | Azt derivatives exhibiting spermicidal and anti-viral activity |
US6350736B1 (en) | 1998-06-29 | 2002-02-26 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US6482805B2 (en) * | 1998-03-25 | 2002-11-19 | Parker Hughes Institute | AZT derivatives exhibiting spermicidal and anti-viral activity |
WO2002094844A2 (en) * | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
US6911424B2 (en) | 1998-02-25 | 2005-06-28 | Emory University | 2′-fluoronucleosides |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
US10100076B2 (en) | 2000-10-18 | 2018-10-16 | Gilead Pharmasset Llc | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
-
1993
- 1993-12-20 CA CA 2130265 patent/CA2130265A1/en not_active Abandoned
- 1993-12-20 EP EP94902577A patent/EP0626970A1/en not_active Withdrawn
- 1993-12-20 WO PCT/CA1993/000553 patent/WO1994014831A1/en not_active Application Discontinuation
- 1993-12-20 AU AU56910/94A patent/AU5691094A/en not_active Abandoned
Non-Patent Citations (7)
Title |
---|
H. BLANCHARD ET AL,: "Structure of (+)-(5R,6R)-5-Chloro-6-methoxy-5,6-dihydro- 1-(2',3'-didehydro-2',3'-dideoxy-beta-D-gly cero-2-enopentofuranosyl)thymine", ACTA CRYST., vol. 49, 1993 * |
H. MITSUYA ET AL,: "Molecular Targets for AIDS Therapy", SCIENCE, vol. 249, September 1990 (1990-09-01), XP000887282, DOI: doi:10.1126/science.1699273 * |
STN International, File CA, Chemical Abstracts, volume 110, no. 1, 2 January 1989 (Columbus, Ohio, US), Chu Chung K. et al: "Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells",Biochem. Pharmacol., 37(19), 3543-8 * |
STN International, File CA, Chemical Abstracts, volume 110, no. 13, 27 March 1989 (Columbus, Ohio, US), Chu Chung K. et al: "Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells", J. Med. Chem., 32(3), 612-17 * |
STN International, File CA, Chemical Abstracts, volume 114, no. 21, 27 May 1991 (Columbus, Ohio, US), Cretton Erika M. et al: "Catabolism of 3'- -azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino- -3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells", Mol. Pharmacol., 39(2), 258-66 * |
STN International, File CA, Chemical Abstracts, volume 115, no. 11, 16 September 1991 (Columbus, Ohio, US), Lien Eric J. et al: "Physical factors contributing to the partition coefficient and retention time of 2'3'-dideoxynucleoside analogs", J. Pharm. Sci., 80(6), 517-21 * |
STN International, File CA, Chemical Abstracts, volume 81, no. 25, 23 December 1974 (Columbus Ohio, US), B. Fouque et al: "Inhibition of Ehrlich ascitescell thymidine kinase by a new class of nucleoside derivatives", abstract no. 165382m, & Chemotherapy (Basel), 20(4), 221-6 1974 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892025A (en) * | 1990-02-01 | 1999-04-06 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
US6346627B1 (en) | 1990-02-01 | 2002-02-12 | Emory University | Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers |
US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US5827727A (en) * | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US7419966B2 (en) | 1995-01-27 | 2008-09-02 | Emory University | [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5905070A (en) * | 1995-01-27 | 1999-05-18 | Emory University | 5--Caboxamido or 5--fluoro!-- 2', 3'--unsaturated or 3'--modified!--pyrimidine nucleosides |
WO1996022778A1 (en) * | 1995-01-27 | 1996-08-01 | Emory University | Derivatives of succinamide and their use as metalloproteinase inhibitor |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6680303B2 (en) | 1995-01-27 | 2004-01-20 | Emory University | 3′,5-difluoro-2′,3′-didehydropyrimidine nucleosides and methods of treatment therewith |
US7662938B2 (en) | 1998-02-25 | 2010-02-16 | Emory University | 2′-fluoronucleosides |
EP2392580A1 (en) | 1998-02-25 | 2011-12-07 | Emory University | 2'-fluoronucleosides |
US9180138B2 (en) | 1998-02-25 | 2015-11-10 | University Of Georgia Research Foundation, Inc. | 2′-fluoronucleosides |
US8168583B2 (en) | 1998-02-25 | 2012-05-01 | University Of Georgia Research Foundation, Inc. | 2-fluoronucleosides |
EP2390257A1 (en) | 1998-02-25 | 2011-11-30 | Emory University | 2'-fluoronucleosides |
US7307065B2 (en) | 1998-02-25 | 2007-12-11 | Emory University | 2′-Fluoronucleosides |
US6911424B2 (en) | 1998-02-25 | 2005-06-28 | Emory University | 2′-fluoronucleosides |
US6191120B1 (en) | 1998-03-25 | 2001-02-20 | Wayne Hughes Institute | Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions |
US6482805B2 (en) * | 1998-03-25 | 2002-11-19 | Parker Hughes Institute | AZT derivatives exhibiting spermicidal and anti-viral activity |
WO1999048902A1 (en) * | 1998-03-25 | 1999-09-30 | Parker Hughes Institute | Azt derivatives exhibiting spermicidal and anti-viral activity |
US6407078B1 (en) * | 1998-03-25 | 2002-06-18 | Parker Hughes Institute | AZT derivatives exhibiting spermicidal and anti-viral activity |
US6503890B1 (en) | 1998-06-29 | 2003-01-07 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US6670336B1 (en) | 1998-06-29 | 2003-12-30 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US6350736B1 (en) | 1998-06-29 | 2002-02-26 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US6537975B1 (en) | 1998-06-29 | 2003-03-25 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US7071176B2 (en) | 1998-06-29 | 2006-07-04 | Parker Hughes Institute | Aryl phosphate derivatives of AZT having anti-HIV activity |
US6528495B1 (en) | 1998-06-29 | 2003-03-04 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US10100076B2 (en) | 2000-10-18 | 2018-10-16 | Gilead Pharmasset Llc | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US7589077B2 (en) | 2001-05-18 | 2009-09-15 | Rakesh Kumar | Antiviral nucleosides |
EP2322534A1 (en) * | 2001-05-18 | 2011-05-18 | Rakesh Kumar | Antiviral nucleosides |
WO2002094844A2 (en) * | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
US8227594B2 (en) | 2001-05-18 | 2012-07-24 | Rakesh Kumar | Antiviral nucleosides |
WO2002094844A3 (en) * | 2001-05-18 | 2003-08-21 | Rakesh Kumar | Antiviral nucleosides |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
Also Published As
Publication number | Publication date |
---|---|
CA2130265A1 (en) | 1994-07-07 |
EP0626970A1 (en) | 1994-12-07 |
AU5691094A (en) | 1994-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Herdewijn et al. | 3'-Substituted 2', 3'-dideoxynucleoside analogs as potential anti-HIV (HTLV-III/LAV) agents | |
US5668113A (en) | Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral infections | |
CA2514466C (en) | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | |
US4963662A (en) | Fluorinated nucleosides and method for treating retrovirus infections therewith | |
CA1339448C (en) | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | |
US4837311A (en) | Anti-retroviral compounds | |
US4892865A (en) | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents | |
WO1990012023A1 (en) | Antiviral compounds | |
JP2003532735A (en) | Antiviral pyrimidine nucleosides | |
JPH05506240A (en) | 5-Benzylbarbiturate derivative | |
US5219840A (en) | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives | |
WO1994014831A1 (en) | Dihydropyrimidine nucleosides with antiviral properties | |
EP0129984B1 (en) | Novel 2'-deoxy-5-substituted uridine derivatives, processes for preparing the same and antitumor agent containing the same | |
US5192749A (en) | 4'-substituted nucleosides | |
WO2003053989A1 (en) | Masked phosphate containing nucleoside derivatives and their use as antivirals | |
AU636678B2 (en) | Nucleoside derivatives | |
JPH04500968A (en) | nucleoside derivatives | |
US5153180A (en) | Fluorinated nucleosides and process for treating retrovirus infections therewith | |
US5527900A (en) | N3-alkyl-2',5'-0-silylated-3'-spiro-thymidine derivatives | |
US4954485A (en) | 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them | |
WO1990003978A1 (en) | 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application | |
US5126347A (en) | Isomeric dideoxynuclesides | |
WO2002074910A2 (en) | Selective anti-viral nucleoside chain terminators | |
WO1994021658A1 (en) | Antiviral imidazolinone nucleoside derivatives | |
USRE33887E (en) | Anti-retroviral compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2130265 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994902577 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 258843 Country of ref document: NZ |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994902577 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994902577 Country of ref document: EP |